Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment BioPharma DiveJournavx revived an area of development long considered a graveyard.Pain & AnaesthesiaRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioPharma Dive Journavx revived an area of development long considered a graveyard. Pain & Anaesthesia Read full story Post navigation Previous: FDA weighs drug repurposing pathway for underserved diseasesNext: Novo says high-dose Wegovy can cause 28% weight loss Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026